NEW YORK, Nov. 15, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ: LGND). Such investors are advised to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/lgnd.
The investigation concerns whether Ligand and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On November 9, 2016, Ligand revealed that it would delay its Quarterly Report for the quarter ended September 30, 2016 on Form 10-Q and that it may issue a restatement. On November 14, 2016 Ligand said it would restate its four financial statements for the quarters ended September 30, 2015; December 31, 2015; March 31, 2016; and June 30, 2016, due to a material error and said its management stated that the Company did not maintain effective controls over the accuracy and presentation of accounting for income taxes related to complex transactions. If you are aware of any facts relating to this investigation, or purchased Ligand shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/lgnd. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.